Immuron Limited Announces Participation in the LD Micro Invitational XIII
Immuron Limited Announces Participation in the LD Micro Invitational XIII
Melbourne, Australia--(Newsfile Corp. - May 16, 2023) - Immuron Limited (ASX: IMC) (NASDAQ: IMRN) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, California on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private 1:1 meetings.
澳大利亞墨爾本--（Newsfile Corp.-2023 年 5 月 16 日）- Immuron 有限公司 澳大利亞證券交易所股票代碼：IMC）（納斯達克股票代碼：IMRN）今天宣佈，它將參加2023年6月6日至8日在加利福尼亞州豪華日落大道酒店舉行的第13屆年度LD Micro邀請賽。預計該活動將有150多家公司參加，以半小時爲單位進行演講，以及一對一的私人會議。
Immuron Limited is scheduled to present on June 6th at 02:00 PM PT. Steven Lydeamore, CEO, will be leading the presentation.
Immuron Limited計劃於太平洋時間6月6日下午 2:00 上市。首席執行官史蒂芬·萊德亞莫爾將主持演講。
We invited interested parties to register for the event here:
我們邀請感興趣的各方在這裏註冊參加活動：
About Immuron Limited
Immuron Limited簡介
Immuron Limited is commercializing and developing a novel class of specifically targeted polyclonal antibodies which are delivered within the gastrointestinal tract and do not cross into the bloodstream. Products in clinical development have the potential to transform standard of care for moderate to severe Campylobacteriosis, Clostridioides difficile infections, Enterotoxigenic Escherichia coli (ETEC) infections and Traveler's Diarrhea. Immuron markets Travelan in Australia, Canada and the U.S. In Australia, Travelan is indicated to reduce the risk of travelers' diarrhea and to reduce the risk of minor gastro-intestinal disorders. In Canada, Travelan is indicated to reduce the risk of travelers' diarrhea. In the U.S, Travelan is a dietary supplement for digestive tract protection.
Immuron Limited正在商業化和開發一類新的特異性靶向多克隆抗體，這些抗體在胃腸道內輸送，不會進入血液。臨床開發中的產品有可能改變中度至重度彎曲桿菌病、艱難梭菌感染、產腸毒素大腸桿菌 (ETEC) 感染和旅行者腹瀉的治療標準。Immuron 在澳大利亞、加拿大和美國銷售 Travelan。在澳大利亞，Travelan 被認爲可以降低旅行者腹瀉的風險並降低患輕微胃腸道疾病的風險。在加拿大，Travelan被認爲可以降低旅行者腹瀉的風險。在美國，Travelan 是一種保護消化道的膳食補充劑。
About LD Micro
關於 LD Micro
LD Micro, a wholly owned subsidiary of Freedom US Markets, was founded in 2006 with the sole purpose of being an independent resource in the micro-cap space. Whether it is the Index, comprehensive data, or hosting the most significant events annually, LD's sole mission is to serve as an invaluable asset for all those interested in finding the next generation of great companies. For more information on LD Micro, visit .
LD Micro是Freedom US Markets的全資子公司，成立於2006年，其唯一目的是成爲微型股領域的獨立資源。無論是指數、綜合數據，還是每年舉辦最重要的活動，LD的唯一使命都是爲所有有興趣尋找下一代偉大公司的人提供寶貴的資產。有關 LD Micro 的更多信息，請訪問。
To present or register, please get in touch with Dean@ldmicro.com
要出示或註冊，請聯繫 Dean@ldmicro.com
To learn more about Freedom US Markets, visit
要了解有關自由美國市場的更多信息，請訪問
For further information on Immuron Limited:
有關 Immuron Limited 的更多信息：
Steven Lydeamore
CEO
+613 8892 4854
steve@immuron.com
史蒂芬·萊德阿莫爾
首席執行官
+613 8892 4854
steve@immuron.com
譯文內容由第三人軟體翻譯。